TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00982111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
Study: NCT03382119

Intervention type: DEVICE
Intervention: Ultrasound with backscatter imaging
Description: This ultrasound tool gathers data from the waves returning from imaged tissue.

Intervention type: DEVICE
Intervention: Ultrasound with backscatter imaging
Description: This ultrasound tool gathers data from the waves returning from imaged tissue.
Study: NCT02020772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual primary health care
Study: NCT02421926

Intervention type: DRUG
Intervention: IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)
Description: After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
Study: NCT04352257

Intervention type: RADIATION
Intervention: pelvic Ultrasound
Description: pelvic and transrectal ultrasound
Study: NCT02120365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given in place of perampanel during the pre-treatment period and lab session days.
Study: NCT04373473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727
Description: Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727 capsules consists of lyophilized microbiota suspension from well-screened donors. Microbiota from three donors will be combined to make the product.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo capsule will be identical to PRIM-DJ2727 but will not contain intestinal bacteria.
Study: NCT02972541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stenting with neoadjuvant chemotherapy
Description: After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenting with immediate Surgery
Description: After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
Study: NCT04465565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 9% Sodium Chloride (NaCl) IV
Description: 9% Sodiun Chloride (NaCl) ( 20cc/kg) adminstrated intravenously
Study: NCT03008382

Intervention type: DRUG
Group type: OTHER
Intervention: Metoprolol Tartrate Oral Tablet
Description: Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo Oral Tablet
Description: Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
Study: NCT03645304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the experimental group, an elastomeric pump filled with local analgesic solution (total volume 100ml) containing 750mg ropivacaine .~Ropivacaine is local analgesics.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% saline group
Description: Continuous wound infusion device used in this study was ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA) comprised an elastomeric pump maintaining constant pressure to infuse 2ml/hour of analgesic to the wound through a catheter for 50 hours. In all participants, the surgeon inserted a 20-gauge, 6.5-cm, multi-holed soaker catheter through an introducer needle after closure of the transumbilical fascia. The catheter was located in the deep subcutaneous space, above the fascia near the skin incision. In the control group, an elastomeric pump filled with filled with 100ml of 0.9% saline .
Study: NCT00982111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: 75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: 800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
Study: NCT03645304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q Painbuster Silver Soaker
Description: ON-Q Painbuster Silver Soaker (I-Flow Corporation, Lake Forest, CA, USA)
Study: NCT01584635

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peroral Endoscopic Myotomy a less invasive treatment for Achalasia
Description: In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
Study: NCT04225819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Softgel capsules containing 5,000 IU cholecalciferol (Vitamin D3), sunflower oil, beef gelatin, glycerin, water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sfotgel capsules containing sunflower oil, beef gelatin, glycerin, water
Study: NCT02844283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-HGF

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 0.9% NaCl
Study: NCT02391376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: moist heat pack; ;
Description: Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: seed pack
Description: Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gel pack
Description: Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
Study: NCT03730545

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral immunonutrition
Description: Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: enteral immunonutrition
Description: Enteral nutrition was started within 12h at an infusion rate of 20ml per hour for SEN group and 16ml per hour for EIN group in the first 24h. The rates of flow were gradually increasing with 50ml/h in SEN versus 40ml/h in EIN on day 2, 70ml/h versus 56ml/h on day 3 and 100ml/h versus 80ml/h until the 7th day depending on the feeding tolerance.
Study: NCT01354704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: enoxaparin 4000 IU 1 injection/day in subcutaneous.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: enoxaparin 4000 IU 1 injection/day in subcutaneous.
Study: NCT01789528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAZ-AVI
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CXL
Description: IV infusion
Study: NCT02988999

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D-allulose
Description: D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: erythritol
Description: non-calorie sweetener
Study: NCT03763344

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual Cognitive Training (PCT)
Description: Perceptual Cognitive Training (PCT) will be performed by having individuals work with a visual perceptual training software program called NeuroTracker. This device uses Multiple Object Tracking at increasing difficulties to develop high-level brain functions critical to recovery \& cognitive health. By increasing in difficulty with each correct response and decreasing in difficulty when mistakes are made, brain function is constantly challenged. Each session (6 mins) delivers a series of mini-tests where the patient needs to remember key targets, then track them moving among distractors for several seconds and then identify them. Simple to do, but always challenging, NeuroTracker adaptively optimizes difficulty to each patient's level, maximizing cognitive stimulation every step of the way.
Study: NCT03224065

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Genotype detected through GenSeizer high-throughput gene capture technology
Description: The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
Study: NCT00391391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Split, Inactivated, Trivalent Influenza Vaccine
Description: Vaccine (infant dose)
Study: NCT02265575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: rehydration using hyaluronidase-assisted subcutaneous infusion
Study: NCT03097562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond cataract surgery
Description: Catalys create a circular opening for accessing and removing the cataract.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femtosecond cataract surgery
Description: Catalys create a circular opening for accessing and removing the cataract.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond cataract surgery
Description: Catalys create a circular opening for accessing and removing the cataract.
Study: NCT01017991

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Milk based infant formula with probiotic
Description: formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
Study: NCT02758015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Meal

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized Meal

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Meal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine Hydrochloride 1500mg
Description: Betaine hydrochloride (natural supplement) administered after standardized meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine Hydrochloride 3000mg
Description: Betaine hydrochloride (natural supplement) administered after standardized meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine Hydrochloride 4500mg
Description: Betaine hydrochloride (natural supplement) administered after standardized meal.
Study: NCT03208842

Intervention type: RADIATION
Intervention: trans vaginal ultrasound
Description: trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity

Intervention type: RADIATION
Intervention: trans vaginal ultrasound
Description: trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of~---the site of the intrauterine gestational sac in relation to the endometrial cavity
Study: NCT03752112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: Cefixime 400mg taken orally two times a day for 10 consecutive days in non-pregnant women with early syphilis infection

Intervention type: DRUG
Group type: OTHER
Intervention: Benzathine penicillin 2.4 million units
Description: Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
Study: NCT02686879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single vision contact lenses
Study: NCT04356690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 150 mg/m2 administered intravenously once daily on Days 1 and 4.
Study: NCT03760796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Corrie Health Digital Platform
Description: The Corrie Health Digital Platform consists of the Corrie smartphone app for heart attack recovery which is paired with an Apple Watch and Bluetooth-enabled, iHealth blood pressure monitor.
Study: NCT03301142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotherapy
Description: Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions.
Study: NCT02128633

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Description: Manipulated at Novaderme ®, Santa Maria, RS, Brazil.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%
Description: Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
Study: NCT01017991

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Milk based infant formula
Description: supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
Study: NCT02086760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasonography with oral hydration
Description: Before, 30 min and 90 min following oral hydration
Study: NCT02128633

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride neutral NaF gel 2 %
Description: The product had similar appearance and viscosity than others.
Study: NCT00681915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: Oral
Study: NCT02981329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metfomin will be taken daily. The metformin dose will be increased during two time points per subject if protocol dose escalation criteria is met.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires will be completed to assess the impact quality of life

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires will be completed to assess the impact quality of life
Study: NCT06122025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient Access
Description: A 6-month pilot prospective interventional study with an independent groups design.
Study: NCT04659382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab combined to standard chemotherapy (XELOX + bevacizumab) and targeted therapy in patients whose tumour has been made immunogenic by radiotherapy (Therasphere) and ICI (atezolizumab).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therasphere
Description: Therasphere injected to patients to promote the release of neoantigens from their tumour and convert it into an immunogenic tumour.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XELOX
Description: standard chemotherapy for first line treament of metastatic CRC (in pMMR and/or MSS patients)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: standard targeted therapy associated with XELOX for first line treament of metastatic CRC (in pMMR and/or MSS patients)
Study: NCT04788407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Subjects will receive nitazoxanide 500 mg TID for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo TID for 7 days
Study: NCT02978183

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ST266
Description: One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
Study: NCT02086760

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Scintigraphy
Study: NCT03568513

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin
Description: The curcumin food supplement will be administered in the form of capsules. Participants in the treatment arm will take 50 mg twice or three times a day, depending on their body weight. Participants will take the curcumin capsules for eight weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be administered in the form of capsules. Participants in the placebo arm will take a capsule twice or three times a day, depending on their body weight. Participants will take the placebo capsules for eight weeks. The placebo capsule will be similar in size, shape and color to the curcumin capsule and they will contain inert food powder.